Your Shopping Cart Is Empty
| Report Code: A04196 | Aug 2021 | Pages: 226 | ||
| Tables: 146 | Charts: 34 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Minimally Invasive Glaucoma Surgery (migs) Devices Market
Request Now !The minimally invasive glaucoma surgery (MIGS) devices market size generated $298.75 million in 2020 and is projected to reach $5,099.38 million by 2030, growing at a CAGR of 35.0% from 2021 to 2030.Minimally invasive glaucoma surgery devices offer an ab interno approach that spares medication, and conjunctival invasion for the treatment of patients suffering from glaucoma. MIGS devices such as stents, shunts, micro implants, and others are utilized for the treatment of patients with mild-to-moderate glaucoma. Rise in preference for MIGS devices over traditional glaucoma surgical devices has been witnessed over the years, as the former devices are safer, and effective compared to traditional devices. In addition, rise in focus of market players in the development of stents specifically for minimally invasive glaucoma surgeries that can reduce intraocular pressure (IOP) effectively supplements the market growth. Moreover, surge in prevalence of glaucoma, rise in geriatric population prone to varied ophthalmic diseases including glaucoma, and change in demographics globally fuel the growth of the minimally invasive glaucoma surgery (MIGS) devices market.
The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the minimally invasive glaucoma surgery (MIGS) devices market. The COVID-19 pandemic and subsequent economic slowdown has materially impacted the global demand for MIGS devices, which are used in procedures and therapies that are considered elective.
Rise in geriatric population along with increase in prevalence of glaucoma around the world, surge in the demand for combined glaucoma and cataract surgeries and increase in focus of key players in the development of MIGS stents drives the market growth. Moreover, in 2019, AbbVie acquired Allergan plc for eye care products include xen, durysta, ozurdex, and refresh/optive. Regional players are eyeing for their spot in the minimal invasive glaucoma surgery device market with these successful advancements. Thus, increase in adoption of MIGS devices boosts the growth of the market. However, reimbursement barriers regarding MIGS devices and dearth of skilled professionals hamper the market growth. In addition, rapid transition from glaucoma medications to minimally invasive glaucoma surgeries are opportunistic for the minimally invasive glaucoma surgery (MIGS) devices market growth.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, there are only a few vaccines that received emergency approvals for COVID-19 treatment or prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the minimally invasive glaucoma surgery (MIGS) devices market. Glaucoma specialists prefer trabeculectomy procedure for glaucoma surgery. The most commonly performed MIGS procedure was the iStent inject followed by XEN and Preserflo, in minimally invasive glaucoma surgery (MIGS) before the COVID-19 pandemic. Although trabeculectomy remains the most commonly performed established glaucoma surgery, it is being performed with reduced frequency during the COVID-19 pandemic due to the decrease in number of postoperative visits and procedures required.
The minimally invasive glaucoma surgery (MIGS) devices market is segmented on the basis of surgery, target, product, end user, and region. By surgery, the market is bifurcated into glaucoma in conjunction with cataract and standalone glaucoma. By target, the market is divided into trabecular meshwork, suprachoroidal space, and others. By product, the market is classified into MIGS stents, MIGS shunts, and other. By end user, the market is categorized into eye hospitals, ophthalmology clinics, and ambulatory surgical centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By surgery type, the market is categorized into glaucoma in conjunction with cataract and standalone glaucoma. The standalone glaucoma segment dominated the market in 2020 and is anticipated to remain dominant during the forecast period. Key factors, such as increase in geriatric population is prone to glaucoma such as mild to moderate glaucoma conditions, primary angle-closure glaucoma, and secondary angle-closure glaucoma, which is set to drive the growth of the minimally invasive glaucoma surgery (MIGS) devices market.
By target, the market is divided into trabecular meshwork, suprachoroidal space, and others. The trabecular meshwork segment is anticipated to depict significant growth during the forecast period due to ineffective drug delivery witnessed in the glaucoma medication which has propelled the transition of glaucoma treatment from medication to minimally invasive glaucoma surgery (MIGS) devices, thereby augmenting the market growth.
By product, the market is divided into MIGS stents, MIGS shunts and other. The MIGS segment is anticipated to exhibit significant growth during the forecast period. Increase in demand for surgical devices in emerging countries and rise in geriatric population is expected to boost the growth of these segments during the forecast period.
By end user, the market is divided into eye hospitals, ophthalmology clinics, and outpatient surgical centers. The eye hospitals segment is anticipated to depict significant growth during the forecast period and is expected to exhibit a lucrative CAGR during the forecast period. Introduction of advanced surgical devices, shorter waiting time, cost efficiency, and rising awareness about MIGS surgery and treatment devices are expected to boost the segment growth during the forecast period.
By region, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. The Asia-Pacific is anticipated to depict significant growth during the forecast period. Increase in demand for surgical devices in emerging countries is expected to boost the growth of these segments during the forecast period.
The key players operating in the global minimally invasive glaucoma surgery devices market include AbbVie Inc., Asico LLC., Glaukos Corporation, iSTAR Medical SA, Ivantis Inc., Lumenis Ltd., Ziemer Ophthalmic Systems AG, Novartis International AG, Santen Pharmaceutical Co. Ltd., and Carl Zeiss Meditec AG.
Key Benefits For Stakeholders
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report Highlights
| Aspects | Details |
|---|---|
| By Surgery |
|
| By Target |
|
| By Product |
|
| By End User |
|
| By Region |
|
| Key Market Players | GLAUKOS CORPORATION, IVANTIS INC., ZIEMER OPHTHALMIC SYSTEMS AG, LUMENIS LTD., ABBVIE INC. (ALLERGAN), NOVARTIS INTERNATIONAL AG (ALCON INC.), ISTAR MEDICAL SA, CARL ZEISS MEDITEC AG, SANTEN PHARMACEUTICAL CO. LTD., ASICO LLC |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in geriatric population along with surge in prevalence of glaucoma around the world
3.5.1.2.Increase in focus of key players in the development of MIGS stents
3.5.1.3.Rise in the demand for combined glaucoma and cataract surgeries
3.5.2.Restraints
3.5.2.1.Reimbursement barriers regarding MIGS devices
3.5.2.2.Dearth of skilled professionals
3.5.3.Opportunity
3.5.3.1.Rapid transition from glaucoma medications to minimally invasive glaucoma surgeries
3.5.4.Impact analysis
3.6.COVID-19 impact analysis on the minimally invasive glaucoma surgery (MIGS) devices market
CHAPTER 4:MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY
4.1.Overview
4.1.1.Market size and forecast
4.2.GLAUCOMA IN CONJUNCTION WITH CATARACT
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.STANDALONE GLAUCOMA
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
CHAPTER 5:MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET
5.1.Overview
5.1.1.Market size and forecast
5.2.TRABECULAR MESHWORK
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.SUPRACHOROIDAL SPACE
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Others
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
CHAPTER 6:MINIMALLYLY INVASIVE GLAUCOMA PRODUCT (MIGS) DEVICES MARKET, BY PRODUCT
6.1.Overview
6.1.1.Market size and forecast
6.2.MIGS STENTS
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.MIGS SHUNTS
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.OTHER (TRABECTOME/MICRO-IMPLANTS/MICRO-CATHETERS)
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
CHAPTER 7:MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.EYE HOSPITALS
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market analysis, by country
7.3.OPHTHALMOLOGY CLINICS
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market analysis, by country
7.4.OUTPATIENT SURGICAL CENTERS
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by region
7.4.3.Market analysis, by country
CHAPTER 8:MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, Key growth factors and opportunities
8.2.2.Market size and forecast, by country
8.2.2.1.U.S.
8.2.2.1.1.U.S. Minimally invasive glaucoma surgery devices market by surgery
8.2.2.1.2.U.S. Minimally invasive glaucoma surgery devices market by target
8.2.2.1.3.U.S. Minimally invasive glaucoma surgery devices market by product
8.2.2.1.4.U.S. Minimally invasive glaucoma surgery devices market by end user
8.2.2.2.Canada
8.2.2.2.1.Canada Minimally invasive glaucoma surgery devices market by surgery
8.2.2.2.2.Canada Minimally invasive glaucoma surgery devices market by target
8.2.2.2.3.Canada Minimally invasive glaucoma surgery devices market by product
8.2.2.2.4.Canada Minimally invasive glaucoma surgery devices market by end user
8.2.2.3.Mexico
8.2.2.3.1.Mexico Minimally invasive glaucoma surgery devices market by surgery
8.2.2.3.2.Mexico Minimally invasive glaucoma surgery devices market by target
8.2.2.3.3.Mexico Minimally invasive glaucoma surgery devices market by product
8.2.2.3.4.Mexico Minimally invasive glaucoma surgery devices market by end user
8.2.3.Market size and forecast, by surgery
8.2.4.Market size and forecast, by target
8.2.5.Market size and forecast, by product
8.2.6.Market size and forecast, by end user
8.3.Europe
8.3.1.Key market trends, key growth factors and opportunities
8.3.2.Market size and forecast
8.3.2.1.Germany
8.3.2.1.1.Germany Minimally invasive glaucoma surgery devices market by surgery
8.3.2.1.2.Germany Minimally invasive glaucoma surgery devices market by target
8.3.2.1.3.Germany Minimally invasive glaucoma surgery devices market by product
8.3.2.1.4.Germany Minimally invasive glaucoma surgery devices market by end user
8.3.2.2.France
8.3.2.2.1.France Minimally invasive glaucoma surgery devices market by surgery
8.3.2.2.2.France Minimally invasive glaucoma surgery devices market by target
8.3.2.2.3.France Minimally invasive glaucoma surgery devices market by product
8.3.2.2.4.France Minimally invasive glaucoma surgery devices market by end user
8.3.2.3.Italy
8.3.2.3.1.Italy Minimally invasive glaucoma surgery devices market by surgery
8.3.2.3.2.Italy Minimally invasive glaucoma surgery devices market by target
8.3.2.3.3.Italy Minimally invasive glaucoma surgery devices market by product
8.3.2.3.4.Italy Minimally invasive glaucoma surgery devices market by end user
8.3.2.4.Spain
8.3.2.4.1.Spain Minimally invasive glaucoma surgery devices market by surgery
8.3.2.4.2.Spain Minimally invasive glaucoma surgery devices market by target
8.3.2.4.3.Spain Minimally invasive glaucoma surgery devices market by product
8.3.2.4.4.Spain Minimally invasive glaucoma surgery devices market by end user
8.3.2.5.UK
8.3.2.5.1.UK Minimally invasive glaucoma surgery devices market by surgery
8.3.2.5.2.UK Minimally invasive glaucoma surgery devices market by target
8.3.2.5.3.UK Minimally invasive glaucoma surgery devices market by product
8.3.2.5.4.UK Minimally invasive glaucoma surgery devices market by end user
8.3.2.6.Rest of Europe
8.3.2.6.1.Rest of Europe Minimally invasive glaucoma surgery devices market by surgery
8.3.2.6.2.Rest of Europe Minimally invasive glaucoma surgery devices market by target
8.3.2.6.3.Rest of Europe Minimally invasive glaucoma surgery devices market by product
8.3.2.6.4.Rest of Europe Minimally invasive glaucoma surgery devices market by end user
8.3.3.Market size and forecast, by surgery
8.3.4.Market size and forecast, by target
8.3.5.Market size and forecast, by product
8.3.6.Market size and forecast, by end user
8.4.Asia-Pacific
8.4.1.Key market trends, key growth factors and opportunities
8.4.2.Market size and forecast, by country
8.4.2.1.Japan
8.4.2.1.1.Japan Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.1.2.Japan Minimally invasive glaucoma surgery devices market, by target
8.4.2.1.3.Japan Minimally invasive glaucoma surgery devices market, by product
8.4.2.1.4.Japan Minimally invasive glaucoma surgery devices market, by end user
8.4.2.2.China
8.4.2.2.1.China Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.2.2.China Minimally invasive glaucoma surgery devices market, by target
8.4.2.2.3.China Minimally invasive glaucoma surgery devices market, by product
8.4.2.2.4.China Minimally invasive glaucoma surgery devices market, by end user
8.4.2.3.India
8.4.2.3.1.India Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.3.2.India Minimally invasive glaucoma surgery devices market, by target
8.4.2.3.3.India Minimally invasive glaucoma surgery devices market, by product
8.4.2.3.4.India Minimally invasive glaucoma surgery devices market, by end user
8.4.2.4.Australia
8.4.2.4.1.Australia Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.4.2.Australia Minimally invasive glaucoma surgery devices market, by target
8.4.2.4.3.Australia Minimally invasive glaucoma surgery devices market, by product
8.4.2.4.4.Australia Minimally invasive glaucoma surgery devices market, by end user
8.4.2.5.South Korea
8.4.2.5.1.South Korea Minimally invasive glaucoma surgery devices market, by surgery
8.4.2.5.2.South Korea Minimally invasive glaucoma surgery devices market, by target
8.4.2.5.3.South Korea Minimally invasive glaucoma surgery devices market, by product
8.4.2.5.4.South Korea Minimally invasive glaucoma surgery devices market, by end user
8.4.2.6.Rest of Asia-Pacific
8.4.2.6.1.Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.4.2.6.2.Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by target
8.4.2.6.3.Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by product
8.4.2.6.4.Rest of Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.4.3.Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.4.4.Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by target
8.4.5.Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by product
8.4.6.Asia-Pacific Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.LAMEA
8.5.1.Key market trends, Key growth factors and opportunities
8.5.2.Market size and forecast, by country
8.5.2.1.Brazil
8.5.2.1.1.Brazil Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.1.2.Brazil Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.1.3.Brazil Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.1.4.Brazil Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.2.Turkey
8.5.2.2.1.Turkey Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.2.2.Turkey Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.2.3.Turkey Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.2.4.Turkey Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.3.Saudi Arabia
8.5.2.3.1.Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.3.2.Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.3.3.Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.3.4.Saudi Arabia Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.4.South Africa
8.5.2.4.1.South Africa Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.4.2.South Africa Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.4.3.South Africa Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.4.4.South Africa Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.2.5.Rest of LAMEA
8.5.2.5.1.Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.2.5.2.Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.2.5.3.Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.2.5.4.Rest of LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by end user
8.5.3.LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by surgery
8.5.4.LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by target
8.5.5.LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by product
8.5.6.LAMEA Minimally invasive glaucoma surgery (MIGS) devices, by end user
CHAPTER 9:COMPANY PROFILES
9.1.ABBVIE INC. (ALLERGAN)
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.ASICO LLC
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.3.GLAUKOS CORPORATION
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments
9.4.ISTAR MEDICAL SA
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Key strategic moves and developments
9.5.IVANTIS INC.
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Key strategic moves and developments
9.6.LUMENIS LTD.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Key strategic moves and developments
9.7.ZIEMER OPHTHALMIC SYSTEMS AG
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.8.NOVARTIS INTERNATIONAL AG (ALCON INC.)
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.SANTEN PHARMACEUTICAL CO. LTD.
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.CARL ZEISS MEDITEC AG
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 02.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR GLAUCOMA IN CONJUNCTION WITH CATARACT, BY REGION, 2020-2030 ($MILLION)
TABLE 03.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR STANDALONE GLAUCOMA, BY REGION, 2020-2030 ($MILLION)
TABLE 04.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 05.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR TRABECULAR MESHWORK, BY REGION, 2020-2030 ($MILLION)
TABLE 06.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR SUPRACHOROIDAL SPACE, BY REGION, 2020-2030 ($MILLION)
TABLE 07.MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER TARGET, BY REGION, 2020-2030 ($MILLION)
TABLE 08.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 09.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS STENTS, BY REGION, 2020-2030 ($MILLION)
TABLE 10.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS SHUNTS, BY REGION, 2020-2030 ($MILLION)
TABLE 11.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER, BY REGION, 2020-2030 ($MILLION)
TABLE 12.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 13.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR EYE HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 14.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OPHTHALMOLOGY CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OUTPATIENT SURGICAL CENTERS, BY REGION, 2020-2030 ($MILLION)
TABLE 16.MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY REGION ($MILLION), 2020-2030
TABLE 17.NORTH AMERICA: MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY COUNTRY ($MILLION), 2020-2030
TABLE 18.U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 19.U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 20.U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 21.U.S. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 22.CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 23.CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 24.CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25.CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 26.MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 27.MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 28.MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29.MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30.NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY ($MILLION), 2020-2030
TABLE 31.NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET ($MILLION), 2020-2030
TABLE 32.NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT ($MILLION), 2020-2030
TABLE 33.NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER ($MILLION), 2020-2030
TABLE 34.EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY COUNTRY ($MILLION), 2020-2030
TABLE 35.GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 36.GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 37.GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 38.GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 39.FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 40.FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 41.FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 42.FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43.ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 44.ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 45.ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 46.ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47.SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 48.SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2021–2028 ($MILLION)
TABLE 49.SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2021–2028 ($MILLION)
TABLE 50.SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2021–2028 ($MILLION)
TABLE 51.UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 52.UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 53.UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 54.UK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 55.REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 56.REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 57.REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 58.REST OF EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59.EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY ($MILLION), 2020-2030
TABLE 60.EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET ($MILLION), 2020-2030
TABLE 61.EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT ($MILLION), 2020-2030
TABLE 62.EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER ($MILLION), 2020-2030
TABLE 63.ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 64.JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 65.JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 66.JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 67.JAPAN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68.CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 69.CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 70.CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 71.CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72.INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 73.INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 74.INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 75.INDIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 76.AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2021–2028 ($MILLION)
TABLE 77.AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 78.AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 79.AUSTRALIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 80.SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY SURGERY, 2020-2030 ($MILLION)
TABLE 81.SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY TARGET, 2020-2030 ($MILLION)
TABLE 82.SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 83.SOUTH KOREA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 84.REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY, 2020-2030 ($MILLION)
TABLE 85.REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET, 2020-2030 ($MILLION)
TABLE 86.REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 87.REST OF ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER, 2020-2030 ($MILLION)
TABLE 88.ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY, 2020-2030 ($MILLION)
TABLE 89.ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET, 2020-2030 ($MILLION)
TABLE 90.ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 91.ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER, 2020-2030 ($MILLION)
TABLE 92.LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY COUNTRY ($MILLION), 2020-2030
TABLE 93.BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 94.BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 95.BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 96.BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 97.TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 98.TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 99.TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 100.TURKEY MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 101.SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 102.SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 103.SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 104.SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 105.SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 106.SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 107.SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT ($MILLION), 2020-2030
TABLE 108.SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER($MILLION), 2020-2030
TABLE 109.REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY ($MILLION), 2020-2030
TABLE 110.REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET ($MILLION), 2020-2030
TABLE 111.REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT($MILLION), 2020-2030
TABLE 112.REST OF LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER ($MILLION), 2020-2030
TABLE 113.LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY SURGERY, 2020-2030 ($MILLION)
TABLE 114.LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY TARGET, 2020-2030 ($MILLION)
TABLE 115.LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 116.LAMEA MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES, BY END USER, 2020-2030 ($MILLION)
TABLE 117.ABBVIE: COMPANY SNAPSHOT
TABLE 118.ABBVIE: OPERATING SEGMENTS
TABLE 119.ABBVIE: PRODUCT PORTFOLIO
TABLE 120.ASICO: COMPANY SNAPSHOT
TABLE 121.ASICO: OPERATING SEGMENTS
TABLE 122.ASICO: PRODUCT PORTFOLIO
TABLE 123.GLAUKOS: COMPANY SNAPSHOT
TABLE 124.GLAUKOS: OPERATING SEGMENTS
TABLE 125.GLAUKOS: PRODUCT PORTFOLIO
TABLE 126.ISTAR: COMPANY SNAPSHOT
TABLE 127.ISTAR: OPERATING SEGMENTS
TABLE 128.ISTAR: PRODUCT PORTFOLIO
TABLE 129.IVANTIS: COMPANY SNAPSHOT
TABLE 130.IVANTIS: OPERATING SEGMENTS
TABLE 131.IVANTIS: PRODUCT PORTFOLIO
TABLE 132.LUMENIS: COMPANY SNAPSHOT
TABLE 133.LUMENIS: OPERATING SEGMENTS
TABLE 134.LUMENIS: PRODUCT PORTFOLIO
TABLE 135.ZIEMER: COMPANY SNAPSHOT
TABLE 136.ZIEMER: OPERATING SEGMENTS
TABLE 137.ZIEMER: PRODUCT PORTFOLIO
TABLE 138.NOVARTIS: COMPANY SNAPSHOT
TABLE 139.NOVARTIS: OPERATING SEGMENTS
TABLE 140.NOVARTIS: PRODUCT PORTFOLIO
TABLE 141.SANTEN: COMPANY SNAPSHOT
TABLE 142.SANTEN: OPERATING SEGMENTS
TABLE 143.SANTEN: PRODUCT PORTFOLIO
TABLE 144.ZEISS: COMPANY SNAPSHOT
TABLE 145.ZEISS: OPERATING SEGMENTS
TABLE 146.ZEISS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.SEGMENTATION OF MINIMALLY INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR GLAUCOMA IN CONJUNCTION WITH CATARACT, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR STANDALONE GLAUCOMA, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR TRABECULAR MESHWORK, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR SUPRACHOROIDAL SPACE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF MINIMAL INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER TARGET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS STENTS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR MIGS SHUNTS BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF GUINEA PIGS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OTHER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR EYE HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OPHTHALMOLOGY CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET FOR OUTPATIENT SURGICAL CENTERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26.GLAUKOS: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.GLAUKOS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28.NOVARTIS: NET SALES, 2018-2020, ($MILLION)
FIGURE 29.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31.SANTEN: NET SALES, 2018–2020, ($MILLION)
FIGURE 32.ZEISS: REVENUE, 2018–2020 ($MILLION)
FIGURE 33.ZEISS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.ZEISS: REVENUE SHARE BY REGION, 2020 (%)
This section provides various opinions of the top-level CXOs in the minimally invasive glaucoma surgery (MIGS) devices market. In accordance with several interviews conducted, the utilization of minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma is expected to increase due to rise in development of new MIGS devices across the globe. North America is projected to be the highest revenue contributor, whereas Asia-Pacific is expected to offer lucrative opportunities to the key players in this market.
According to the perspectives of CXOs of leading companies in the market, rise in burden of geriatric population that is susceptible to glaucoma, increase in demand for surgeries combining glaucoma, and cataract, and surge in geriatric population susceptible to glaucoma boost the market growth. However, unfavorable reimbursement for minimally invasive glaucoma surgery devices, and dearth of skilled professionals are anticipated to hamper the market growth. Glaucoma in conjunction with cataract segment dominates the global MIGS market in 2020 and is anticipated to maintain this dominance throughout the forecast period as these MIGS devices are highly utilized in these surgeries. Several market players are focused toward developing minimally invasive glaucoma surgery (MIGS) devices that can be ideal for the lowering of intraocular pressure including mini shunts, stents, and micro-implants. According to the CXOs, majority of the manufacturers and distributors have focused on expanding their presence in emerging economies.
A. Yes, global minimally invasive glaucoma surgery (MIGS) devices companies are profiled in the report
A. The top companies that hold the market share in global minimally invasive glaucoma surgery (MIGS) devices market are AbbVie Inc., Asico LLC., Glaukos Corporation, iSTAR Medical SA, Ivantis Inc., Lumenis Ltd., Ziemer Ophthalmic Systems AG, Novartis International AG, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG.
A. The key trends in the global minimally invasive glaucoma surgery (MIGS) devices market are reducing intraocular pressure (IOP) effectivel and increase in geriatric population is prone to glaucoma such as mild to moderate glaucoma conditions, primary angle-closure glaucoma, and secondary angle-closure glaucoma, which is set to drive the growth of this market .
A. The market value of global minimally invasive glaucoma surgery (MIGS) devices market will reach $5,099.38 million by 2030
A. The forecast period in the report is from 2021 to 2030
A. The total market value of global minimally invasive glaucoma surgery (MIGS) devices market was $298.75 million in 2020
A. The base year for the report is 2020
Start reading instantly.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report